نتایج جستجو برای: cll blood cancer

تعداد نتایج: 1557686  

2011
Ozlem D. ISERI Meltem D. KARS Pelin MUTLU Ferit AVCU Ali U. URAL Ufuk GUNDUZ

One of the major problems in treatment of leukemias is multidrug resistance, which is already present at diagnosis or develops after chemotherapy. The gene expression levels of multidrug resistance resistance 1 (MDR1), breast cancer resistance protein (BCRP) and lung resistance-resistance protein (LRP) were evaluated in blood samples of 20 CLL and 24 CML patients using RT-PCR. MDR1, BCRP and LR...

2015
Charles H. Lawrie

Chronic lymphocytic leukaemia (CLL) is themost common adult leuvariability in the choice of starting material (i.e. exosomes, sera or plaskaemia in the Western world and is characterized by the accumulation of CD5+/CD19+/CD23+ mature B cells in the peripheral blood, bone marrow and lymphoid tissue of patients. Despite major improvements in therapy over the past decades, CLL remains essentially ...

Journal: :Blood 2015
Henrik Hjalgrim Klaus Rostgaard Senthil K Vasan Henrik Ullum Christian Erikstrup Ole B V Pedersen Kaspar R Nielsen Kjell-Einar Titlestad Mads Melbye Olof Nyrén Gustaf Edgren

Monoclonal B-cell lymphocytosis (MBL) is a precursor of chronic lymphocytic leukemia (CLL). Observations of MBL in blood donors raise concern that transmitted MBL may cause recipient CLL. Using a database with health information on 1.5 million donors and 2.1 million recipients, we compared CLL occurrence among 7413 recipients of blood from 796 donors diagnosed with CLL after donation cessation,...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
M Palma P Kokhaei J Lundin A Choudhury H Mellstedt A Osterborg

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the progressive accumulation of functionally incompetent, mature looking, monoclonal CD5+, CD23+ B lymphocytes in blood, bone marrow, lymph nodes and spleen/liver. CLL B cells express low levels of surface immunoglobulin (Ig)M, IgD (10% of those on normal B cells), CD21, CD22 and CD79b. Close to 99% of B-CLL lymphocytes in peripher...

2018
Sascha Dietrich Małgorzata Oleś Junyan Lu Leopold Sellner Simon Anders Britta Velten Bian Wu Jennifer Hüllein Michelle da Silva Liberio Tatjana Walther Lena Wagner Sophie Rabe Sonja Ghidelli-Disse Marcus Bantscheff Andrzej K. Oleś Mikołaj Słabicki Andreas Mock Christopher C. Oakes Shihui Wang Sina Oppermann Marina Lukas Vladislav Kim Martin Sill Axel Benner Anna Jauch Lesley Ann Sutton Emma Young Richard Rosenquist Xiyang Liu Alexander Jethwa Kwang Seok Lee Joe Lewis Kerstin Putzker Christoph Lutz Davide Rossi Andriy Mokhir Thomas Oellerich Katja Zirlik Marco Herling Florence Nguyen-Khac Christoph Plass Emma Andersson Satu Mustjoki Christof von Kalle Anthony D. Ho Manfred Hensel Jan Dürig Ingo Ringshausen Marc Zapatka Wolfgang Huber Thorsten Zenz

As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. ...

  High level of CMV-specific CD4+ and CD8+cells Immune Response and Correlation Between them in B-cell Chronic Lymphocytic Leukemia Patients     B. Pourgheysri [1] , P. Moss [2]     Received: 10/09/07 Sent for Revision: 05/03/08 Received Revised Manuscript: 06/12/08 Accepted: 30/12/08   Background and Objective: Chronic lymphocytic leukemia (CLL) is characterized by a monoclonal proliferation o...

Journal: :European Heart Journal 2021

Abstract Background The overall survival of oncohematological patients (pts) depends not only on the severity cancer, anticancer therapy used and comorbidity pts. most important role in management these pts is played by supervision a cardiologist. Purpose To assess effect active cardiac targeted with ibrutinib. Methods We examined observed dynamics for 5 years 217 chronic lymphocytic leukemia (...

Journal: :Blood 2010
Leila R Martins Paulo Lúcio Milene C Silva Kenna L Anderes Paula Gameiro Maria G Silva João T Barata

Expression of protein kinase CK2 is frequently deregulated in cancer and mounting evidence implicates CK2 in tumorigenesis. Here, we show that CK2 is overexpressed and hyperactivated in chronic lymphocytic leukemia (CLL). Inhibition of CK2 induces apoptosis of CLL cells without significantly affecting normal B and T lymphocytes. Importantly, this effect is not reversed by coculture with OP9 str...

2004
Sanjay Tiwari Kyriacos Felekkis Eun-Yi Moon Amanda Flies David H. Sherr

Type 4 cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE4) inhibitors and other agents that raise intracellular cAMP levels induce apoptosis in Bcell chronic lymphocytic leukemia (BCLL) but not in T-CLL or peripheral blood T cells. Two principal effector proteins for cAMP are protein kinase A (PKA) and EPAC (exchange protein directly activated by cAMP), a Rap guanosine 5 diphosphate ...

2014
Martin Skarzynski Joshua D. Thomas Christopher G. Nelson Alexandre David Georg Aue Terrence R. Burke Christoph Rader Adrian Wiestner

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy in need of new, effective, and safe therapies. The recently identified IgM receptor FcmR is overexpressed on malignant B cells in CLL and mediates the rapid internalization and lysosomal shuttling of IgM via its Fc fragment (Fcm). To exploit this internalization and trafficking pathway for targeted drug delivery, we engineered an IgM-der...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید